What is your business idea, what problem do you want to solve?
“Sprint Bioscience’s goal is to cure more people who are diagnosed with cancer. The large drug companies are looking for innovations to broaden their portfolios of drug projects. They do this through co-operation with small, creative companies such as Sprint Bioscience,” says Anders Åberg, CEO.
“We identify, start and develop drug projects in the pre-clinical phase. The goal is to manage them, together with a licensee, all the way to a finished product. Our business idea is to develop drug candidates that can be new, innovative treatments by tying up as little capital as possible.
Where are you now?
“Following our move to Flemingsberg, we were able to launch our expansion phase. We now have more than 30 employees, most of whom are working on our research projects as drug chemists and cell biologists. We are a public company, listed on the Nasdaq First North Premier, and so far we have one drug project set for clinical testing,” Åberg says.
“Our model differs from how other smaller biotech firms manage and finance drug development. We start new, innovative drug projects and license them in the pre-clinical phase. This allows us to review a project’s commercial value at an earlier stage, and thereby minimize risk in our project portfolio. Today, we’re known in the international drug industry for delivering projects of high quality and high medical relevance.
What are you plans for the future?
“We’re currently adapting our premises to our specific requirements. At last we have modern offices and new labs that are suited to how we work and support our creativity,” says Åberg.
“In the long term, we’ll build a profitable Swedish drug company with an international reputation. We will continue to recruit drug developers and other function to the company.
Why are you in Flemingsberg?
“Flemingsberg offers us the opportunity to grow and provide a good working environment to our employees. Other advantages are the proximity to research at Karolinska Institutet and the clinical research at Karolinska University Hospital. We were also attracted by Flemingsberg as an area that represents new ways of thinking.”